Search results
Results from the WOW.Com Content Network
Antipruritics, abirritants, [1] or anti-itch drugs, are medications that inhibit itching (Latin: pruritus).Itching is often associated with sunburns, allergic reactions, eczema, psoriasis, chickenpox, fungal infections, insect bites and stings like those from mosquitoes, fleas, mites, and contact dermatitis and urticaria caused by plants such as poison ivy (urushiol-induced contact dermatitis ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...
Lithium is approved by the FDA for the treatment of bipolar disorder and is widely prescribed off-label as a treatment for major depressive disorder, [12] often as an augmentation agent. Lithium is recommended for the treatment of schizophrenic disorders only after other antipsychotics have failed; it has limited effectiveness when used alone. [13]
Another class of medications known to occasionally cause itching is known as serotonin reuptake inhibitors. [3] Itching is one of the most frequent adverse effects of opioid therapy. [4] A common artificial colloid used in clinical fluid management is hydroxyethyl starch (HES).
Cholestatic pruritus is the sensation of itch due to nearly any liver disease, but the most commonly associated entities are primary biliary cholangitis, primary sclerosing cholangitis, obstructive choledocholithiasis, carcinoma of the bile duct, cholestasis (also see drug-induced pruritus), and chronic hepatitis C viral infection and other forms of viral hepatitis.
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria.It is synthesized in the liver in some species, and was first identified in bile of bears of genus Ursus, from which its name derived. [8]
Nalfurafine (INN, USAN) [3] (brand name Remitch; former developmental code names TRK-820, AC-820, MT-9938) is an antipruritic (anti-itch drug) that is marketed in Japan for the treatment of uremic pruritus in individuals with chronic kidney disease undergoing hemodialysis.
A study by one of the manufacturers of the drug found the risk of agranulocytosis within the first week of treatment to be a 1.1 in a million, [32] versus 5.9 in a million for diclofenac. [ medical citation needed ] Therapeutic effect of metamizole on intestinal colic is attributed to its analgesic properties, with no evidence of interference ...